Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.

doi:10.1007/s10549-020-05699-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.

Breast cancer research and treatment - 1 Jul 2020

Cragun Deborah, Weidner Anne, Tezak Ann, Clouse Kate, Pal Tuya

Abstract excerpt

PURPOSE: Identification of inherited breast cancer may guide cancer risk management. We sought to compare risk management practices across women with inherited breast cancer genes. METHODS: Females with a pathogenic/likely pathogenic (P/LP) variant in BRCA1/2, PALB2, CHEK2, and/or ATM were surveyed about cancer risk management. Comparisons were made across genes. RESULTS: The 235 participants with P/LP variants...

Topics

Adolescent
Adult
Ataxia Telangiectasia Mutated Proteins
BRCA1 Protein
BRCA2 Protein
Breast Neoplasms
Checkpoint Kinase 2
Fanconi Anemia Complementation Group N Protein
Female
Genetic Carrier Screening
Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Germ-Line Mutation

Guideline Adherence

Hereditary Breast and Ovarian Cancer Syndrome

Heterozygote

Humans

Medical History Taking

Medical Overuse

Source

Open in PubMed

Identifiers

PMID: 32445176
DOI: 10.1007/s10549-020-05699-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.PMID 32445176Read ↗

Association of Moderate-Risk Breast Cancer Genes with Contralateral Prophylactic Mastectomy and Bilateral Disease.Semantic proximity Read ↗

Comparing Cancer Risk Management between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants.Semantic proximity Read ↗

Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).Semantic proximity Read ↗

Factors that differentiate cancer risk management decisions among females with pathogenic/likely pathogenic variants in PALB2, CHEK2, and ATM.Semantic proximity Read ↗

Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations.Semantic proximity Read ↗

Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Semantic proximity Read ↗

Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2.Semantic proximity Read ↗

Breast Cancer Genetics and Indications for Prophylactic Mastectomy.Semantic proximity Read ↗

Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.Semantic proximity Read ↗

Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer.Semantic proximity Read ↗

Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.Semantic proximity Read ↗

Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.